First liquid biopsy test reimbursed in
“This is a very positive development for Novigenix and serves as an important step in our strategy to increase the adoption and acceptance of our current and next generation Colox test in
A precondition for cost coverage is the inclusion of the private outpatient supplemental insurance PRIMEO. Preventive testing can be offered to women and men over the age of 50 who present no symptoms and do not have a personal history of polyps or family history of colorectal cancer. Under the partnership with Novigenix, PRIMEO insureds receive early paid access, in terms of improved medical care, to a non-invasive blood test that meets the latest technological and scientific standards but is not reimbursed by compulsory health insurance, and which, for this reason, is now considered to be a diagnostic innovation of PRIMEO.
The blood test Colox is designed for accurate and reliable detection of adenoma and early stage colorectal cancer. It offers a convenient solution for patients to be tested with no need for bowel or stool preparation. It can be ordered by the physician as part of a routine medical check-up. Individuals testing positive with Colox are referred for follow-up diagnostic colonoscopy and the ones testing negative should continue periodic testing. Based on the tumor-host interaction, Colox measures the immune system reaction to the onset of colorectal cancer. The test analyses the transcriptome of immune cells isolated from a blood sample. The immune cells in the blood change their transcriptomic profiles in presence of growing adenoma and colorectal carcinoma as part of the “host-response”.
PRIMEO is an innovative supplementary insurance that covers outpatient procedures. Patients have an unrestricted choice of doctors, enjoy a high level of comfort and privacy and benefit from attractive supplementary benefits such as check-ups, high-quality implants, innovative diagnosis and treatment forms and much more. For more details please consult www.primeo/insurance
Novigenix is committed to providing a new understanding of the human host response against cancer. The company was founded on the vision that Immuno-Transcriptomics will bring unprecedented advances in diagnosing and treating cancer patients leading to significant improvement in healthcare. Novigenix’s unique Immuno-Transcriptomics technology enables an accelerated identification of disease specific mRNA signatures of circulating immune cells, which combined with machine learning and predictive algorithms, can predict onset and progression of disease. The Company has established a valuable multicultural biobank and database of over 1,400 patients at risk of colorectal cancer (CRC) and has launched its first blood-based molecular diagnostic product, Colox, for the early detection of colon cancer. For more information visit www.novigenix.com.